Home/Filings/4/0001231589-25-000012
4//SEC Filing

MAHON PAUL A 4

Accession 0001231589-25-000012

CIK 0001082554other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 4:32 PM ET

Size

19.0 KB

Accession

0001231589-25-000012

Insider Transaction Report

Form 4
Period: 2025-12-11
MAHON PAUL A
EVP & GENERAL COUNSEL
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-11$146.03/sh+11,000$1,606,33047,781 total
  • Sale

    Common Stock

    2025-12-11$482.22/sh560$270,04447,221 total
  • Sale

    Common Stock

    2025-12-11$483.25/sh900$434,92346,321 total
  • Sale

    Common Stock

    2025-12-11$484.31/sh5,220$2,528,07641,101 total
  • Sale

    Common Stock

    2025-12-11$485.22/sh2,804$1,360,55038,297 total
  • Sale

    Common Stock

    2025-12-11$486.36/sh1,116$542,77737,181 total
  • Sale

    Common Stock

    2025-12-11$487.37/sh400$194,94636,781 total
  • Exercise/Conversion

    Stock Option

    2025-12-1111,00020,250 total
    Exercise: $146.03From: 2020-03-15Exp: 2027-03-15Common Stock (11,000 underlying)
Footnotes (7)
  • [F1]This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024.
  • [F2]This transaction was executed in multiple trades at prices ranging from $481.84 to $482.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $482.88 to $483.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $483.88 to $484.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $484.88 to $485.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $485.90 to $486.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F7]This transaction was executed in multiple trades at prices ranging from $487.24 to $487.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Issuer

UNITED THERAPEUTICS Corp

CIK 0001082554

Entity typeother

Related Parties

1
  • filerCIK 0001231589

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 4:32 PM ET
Size
19.0 KB